A Randomized, Multiple-dose, Multicenter, Comparative Parallel Study To Evaluate The Efficacy, Safety And Pharmacokinetic Characteristics Of Intravenous Infusion Of Rituximab (Hetero) And Reference Medicinal Product (Rituximab, Roche) In Indian Patients Of Non-Hodgkins Lymphoma (HERILY Study)

Hetero Drugs Limited0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•The patient willing to give written, signed, and dated informed consent to participate in the study before initiating any study related procedures
•Male or Female >=18 years and <=65 years of age (both inclusive)
•Histologically confirmed CD20-positive- Newly diagnosed diffuse large B-cell Non-Hodgkinâ??s lymphoma OR Previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy
•Patients who are eligible for rituximab and CHOP
•Patients with at least one measurable lesion as per International Working Group Response Criteria for Malignant Lymphoma
•Adequate liver, renal, cardiac and haematological functions
•Subjects with a performance status of 0 to 2 according to the Eastern Cooperative Oncology Group (ECOG)
•Life expectancy more than six months
•No other serious illness that according to investigator might jeopardize the well-being, the safety of study subjects, the compliance to study medications and validity of data generated during the study.

•Hypersensitivity reactions with murine proteins or planned chemotherapy
•Diffuse lymphoma for which CHOP is not adequate therapy
•Bulky Disease (10 cm on maximum dimension) or involves 1/3 of chest diameter (on radiographic imaging)
•Need for emergency therapy such as neurologic compression syndrome
•Subjects with CNS involvement or CNS lymphoma (Diffuse large B-cell lymphoma that is primary CNS, effusional, or intravascular according to the WHO, 2008 classification)
•Patient treated with prior chemotherapy including not limited to Anthracyclines, Rituximab, anti-CD-20 therapy or autologous or allogeneic stem cell transplantation
•Any radiotherapy given for lymphoma or non-lymphoma before 30 days of planned treatment
•Symptomatic peripheral neuropathy (>=Grade 2,Common Terminology Criteria of Adverse Events [CTCAE v 4.03)
•Patients using systemic antibiotic therapy 30 days prior to screening

发起方